Introduction {#S1}
============

The late-term complications of hematopoietic cell transplantation (HCT) are numerous and include, but are not limited to, chronic graft-vs.-host disease (cGVHD), immunodeficiency, opporunistic infections, liver, pulmonary, and endocrine dysfunction, gonadal failure, and secondary malignancy ([@B1], [@B2]). Slow recovery of blood counts is also a well-recognized complication of transplantation, as well as incomplete engraftment, especially after umbilical cord blood (UCB) grafts and T-cell depleted or *in vitro* manipulated grafts ([@B3]). The incidence of long-term thrombocytopenia varies from 5 to 20% of HCT patients ([@B4]--[@B10]). Cytopenia may be related to transplant specific complications, such as cGVHD, inadequate cell dose of the graft, marrow dysfunction, immunosuppressive medications, and late chemotherapeutic effects ([@B11], [@B12]). Cytopenia after transplant is a predictor of non-relapse mortality ([@B13]--[@B15]). Possible mechanisms of cytopenia after HCT include cytokine-mediated suppression of megakaryopoiesis, erythropoiesis, or lymphopoiesis, and dysfunction of the bone marrow microenvironment ([@B16], [@B17]). Bone marrow stromal cells such as mesenchymal stromal cells (MSCs) elaborate cytokines that nurture or stimulate the marrow microenvironment by several mechanisms ([@B18]--[@B20]). MSCs can act as pericytes, wrapping around the endothelial cells of capillaries and venules and secrete bioactive products that contribute to tissue regeneration ([@B21], [@B22]). MSCs could also be selectively immune-suppressive and could affect the production of inhibitory cytokines ([@B23], [@B24]). Hence, it is possible that administration of MSCs in the setting of incomplete or delayed engraftment can modulate the milieu of the bone marrow microenvironment, through both direct interaction with hematopoietic stem cells (HSCs) and through secretion of cytokines, to improve blood counts posttransplant ([@B25]--[@B27]).

Mesenchymal stromal cells given at the time of HCT have been shown to improve engraftment, as well as have immunomodulatory effects in murine stem cell transplantation models ([@B28], [@B29]). MSCs can be found within multiple site, including adipose tissue and bone marrow ([@B30], [@B31]). The placenta is also an easily available source of cells from mesenchymal origin ([@B32]). PLacental eXpanded (PLX)-R18 (Pluristem Ltd., Haifa, Israel) is a human placental derived mesenchymal-like adherent stromal cells grown *in vitro* in a three-dimensional system. These cells secrete cytokines which contribute to hematopoietic reconstitution and differentiation, including IL-6, MCP-3, HGF, IL-8, FGF-7, GM-CSF, IL-10, and bFGF ([@B33]). Previous studies have demonstrated that intramuscular (IM) injections of PLX-R18 can mitigate mortality from acute radiation syndrome in murine models ([@B33]). PLX-R18 is being developed under the FDA's animal rule for hematopoietic rescue from radiation syndrome. The effects of IM PLX-R18 appear to be related to transient secretion of pro-differentiation and pro-growth cytokines ([@B33], [@B34]).

Because there is no mouse model of delayed or incomplete engraftment, we proposed to administer PLX-R18 posttransplant in a well-established murine model of transplant utilizing sub-optimal doses of human CD34-selected UCB after radiation conditioning. Our hypothesis is that posttransplant IM administration of PLX-R18 will improve human hematopoietic engraftment, as measured by a quantitative improvement in human hematopoietic (CD45), B-cell (CD19), T-cell (CD3), megakaryocytic (CD41), and granulocyte (CD13, CD14) lineages in the peripheral blood and bone marrow.

Materials and Methods {#S2}
=====================

Mice {#S2-1}
----

Non-obese Diabetic--Severe Combined Immunodeficiency--IL2Rgammanull (NSG) mice were obtained from breeding pairs originally purchased from Jackson Laboratories (Bar Harbor, ME, USA). NSG mice were bred in a pathogen-free unit and maintained in sterile cages. Mice were handled and cared with strict adherence to guidelines as established by the Animal Resource Center and following study protocols as approved by the Institutional Animal Care and Use Committee at Case Western Reserve University School of Medicine (IACUC protocol 2015-0118).

PLX-18 {#S2-2}
------

PLacental eXpanded-R18 cells were produced and supplied by Pluristem Therapeutics, Inc. (Haifa, Israel). The PLX-R18 cells are mesenchymal-like adherent stromal cells derived from full-term placentas following Cesarean section. The PLX-R18 production process is composed of two major steps of isolation and culturing of the adherent stromal cells. In the first stage, adherent stromal cells are isolated from the placenta and passaged under two-dimensional cell growth conditions. Cells are then concentrated and cryopreserved. This intermediate cell stock is later thawed, passaged, and subsequently seeded for further expansion in three-dimensional growth in a bioreactor on non-woven fiber-made carriers, from which cells are subsequently harvested and cryopreserved.

PLacental eXpanded-R18 cells have a spindle-like morphology and are characterized by a high expression of typical MSC markers, such as CD105, CD73 and CD29, and lack surface expression of CD45, CD34, CD14, CD19, and HLA-DR. In addition, PLX-R18 does not express CD31 (an endothelial marker) and GlyA (an erythrocyte cell marker) on their surface. PLX-R18 cells exhibit limited capacity to differentiate *in vitro* into osteocytes and adipocytes compared to bone marrow-derived MSCs.

The cells are harvested and cryopreserved in liquid nitrogen as an "off the shelf" allogeneic adult cell source product. Prior to their administration the cells were thawed washed and suspended in Plasmalyte A solution (Baxter, Deerfield, IL, USA).

CD34^+^ Umbilical Cord Cell Isolation {#S2-3}
-------------------------------------

Umbilical cord blood units were received from the Cleveland Cord Blood Center (Cleveland, OH, USA). Each unit was diluted 1:3 with phosphate buffered saline (PBS) + 0.5% Human Serum Albumin (HSA) and layered onto Ficoll Paque PLUS to isolate the mononuclear cells by density gradient. After a cell count and washes, the mononuclear cells were labeled per protocol using the Miltenyi Biotec (Cologne, Germany) CD34 Microbead Kit. The CD34 cells were then isolated using a positive selection column in a magnet and washed three times with MACS buffer. The CD34 cells from both UCB units were combined, counted, and re-suspended in PBS for injection into mice.

Murine Transplantation {#S2-4}
----------------------

NSG mice aged 8--12 weeks were used in all transplant experiments. Prior to transplantation with UCB, recipient mice were ear punched for individual identification. NSG mice received 300 cGy total body irradiation prior to receiving 5 × 10^5^ CD34^+^ selected cells from human UCB, which has been shown to lead to incomplete human hematopoietic recovery ([@B35]). Following non-lethal irradiation (300 cGy), two groups of NSG mice were studied: (1) intravenous (IV) 5 × 10^5^ UCB CD34^+^ cells (*N* = 10) and (2) IV 5 × 10^5^ UBC CD34^+^ cells and 1 × 10^6^ IM PLX-R18 on day 2 (D2) and day 7 (D7) (*N* = 14) (Figure [1](#F1){ref-type="fig"}). Initially, IV and IM injection of PLX-R18 were attempted; however, mice immediately developed fatal acute pulmonary toxicity after IV infusion (even with slow infusion) and thus the IM route obviously was preferred.

![Study design: NSG mice received 300 cGy total body irradiation prior to receiving 5 × 10^5^ CD34^+^ selected cells from human umbilical cord blood (UCB). Following non-lethal irradiation (300 cGy), two groups of NSG mice were studied: (1) intravenous (IV) 5 × 10^5^ UCB CD34^+^ cells and (2) IV 5 × 10^5^ UBC CD34^+^ cells and 1 × 10^6^ intramuscular (IM) PLacental eXpanded (PLX)-R18 on D2 and D7. Peripheral blood from transplant recipient mice were analyzed on weeks 2, 4, 6, and 8. Bone marrow from transplant recipient mice was analyzed on week 8.](fmed-05-00037-g001){#F1}

Injections {#S2-5}
----------

Umbilical cord blood cells were administered *via* tail vein injection suspended in a total volume of 200 µL. IM injections: PLX-18 cells were administered *via* IM right thigh injections suspended in a total volume of 100 µL.

Tissue Harvest and Preparation {#S2-6}
------------------------------

The liver, ileum, ascending colon, and right tibia were harvested and were fixed in 10% buffered formalin, embedded in paraffin, cut into 5-μm thick sections and stained with hematoxylin and eosin for histologic examination. Slides were coded without reference to transplant group or treatment and reviewed in blinded fashion by an independent pathologist (HM).

Flow Cytometry {#S2-7}
--------------

Peripheral blood samples from transplant recipient mice were analyzed on weeks 2, 4, 6, and 8. Bone marrow from transplant recipient mice was analyzed on week 8. Peripheral blood and bone marrow were stained for T cell markers (CD3), myeloid markers (CD45, CD13, CD14, CD41) along with B-cell markers (CD19). All monoclonal antibodies (mAbs) are human specific and were purchased from BD Biosciences Pharmingen (San Diego, CA, USA) or eBioscience (San Diego, CA, USA). At least 1 × 10^5^ events were analyzed per conjugated MAb stain condition. Data were analyzed using CFlow software (Accuri, Ann Arbor, MI, USA). Human engraftment was expressed as percentage of CD45^+^ cells within the gated population of bone marrow or peripheral blood cells. Engraftment of CD45^+^ cell subsets (CD3, CD13, CD14, CD19) was expressed as a percentage within the gated population of bone marrow or peripheral blood cells. Platelet engraftment was expressed as a percentage of CD41^+^ events compared to total peripheral blood or bone marrow cells.

Histology {#S2-8}
---------

An independent hematopathologist, blinded to cohort characteristics, evaluated all tibial sections. The analysis included sections from each mouse in every cohort and was evaluated for myeloid-to-erythroid ratio, cellularity, and megakaryocyte percentages.

Statistics {#S2-9}
----------

All values are expressed as the mean ± SEM. Statistical comparisons between groups were completed using Mann and Whitney test (nonparametric data).

Results {#S3}
=======

Posttransplant IM Administration of PLX-R18 Improves Overall Human Hematopoietic Cell Engraftment (CD45) and B-Cell Engraftment (CD19) in the Peripheral Blood {#S3-1}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

To create a mouse model of incomplete engraftment, we injected sub-optimal dose (1 × 10^5^ cells/mouse) of human UCB-derived CD34^+^ cells into NSG mice following 300 cGy whole-body irradiation. IM of 1 × 106 PLX-R18 were administered on days 2 and 7 following hUCB transplantation (Figure [1](#F1){ref-type="fig"}). Hematopoietic reconstitution analyses were performed every 2 weeks starting 2 weeks following hUCB transplantation. Bi-weekly flow cytometry analysis of the peripheral blood revealed the highest level of human CD45^+^ cells and B-cell engraftment in the IM PLX-R18 cohort at weeks 6 and 8, but not at weeks 2 and 4 (Figure [2](#F2){ref-type="fig"}). Specifically, there was a gradual increase in human CD45 percentage in the IV UCB cohort from week to week, the percentage of human CD45 engraftment in the peripheral blood spiked at week 6 in the IM PLX-R18 cohort, which was statistically significant (8.4 vs. 24.1%, *p* \< 0.001; Figure [2](#F2){ref-type="fig"}A; Table [1](#T1){ref-type="table"}). While a relative decrease in the percentage of human CD45 cells occurred in the peripheral blood of those mice treated with PLX-R18 at week 8 when compared to week 6, it was still superior when compared to the IV hUCB cohort (7.3 vs. 13.1%, *p* \< 0.05, Figure [2](#F2){ref-type="fig"}A; Table [1](#T1){ref-type="table"}). In contrast, mice treated with PLX-R18 demonstrated sustained B-cell engraftment superior to the control cohort at weeks 6 (3.8 vs. 12.6%, *p* \< 0.01, Figure [2](#F2){ref-type="fig"}B; Table [1](#T1){ref-type="table"}) and 8 posttransplant (4.1 vs. 10.1%, *p* \< 0.01; Figure [2](#F2){ref-type="fig"}E; Table [1](#T1){ref-type="table"}). Similar rises in the percentage of human T-cell, granulocyte, and platelet engraftment occurred in the peripheral blood of the PLX-R18 cohort, but these measurements were not statistically different from the IV hUCB cohort (Figures [2](#F2){ref-type="fig"}B--D,F; Table [1](#T1){ref-type="table"}). Representative flow cytometry plots of peripheral blood analysis at 8 weeks posttransplant are shown in Figure [3](#F3){ref-type="fig"}.

![Posttransplant PLacental eXpanded (PLX)-R18 IM injection improves human leukocyte (CD45) and B-cell (CD45/19) engraftment in the peripheral blood. Flow cytometry results of CD45 **(A)**, CD45/CD3 **(B)**, CD45/CD13 **(C)**, CD45/CD14 **(D)**, CD45/CD19 **(E)**, and CD41 **(F)** in the peripheral blood at weeks 2, 4, 6, and 8 weeks are shown. IV UCB, *n* = 9; IV UCB/IM PLX, *n* = 14; IV, intravenous; UCB, umbilical cord blood; IM, intramuscular; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](fmed-05-00037-g002){#F2}

###### 

Summary of the percent CD45, CD45/3, CD45/13, CD45/14, CD45/19, and CD41 in the peripheral blood at 2, 4, 6, and 8 weeks post umbilical cord blood (UCB) infusion.

                                                              Week 2 (%)          Week 4 (%)           Week 6 (%)            Week 8 (%)
  ----------------------------------------------------------- ------------------- -------------------- --------------------- --------------------
  CD45 intravenous (IV) UCB                                   3.2                 5.4                  8.4                   7.4
  CD45 IV UCB + intramuscular (IM) PLacental eXpanded (PLX)   8.7 (*p* \> 0.05)   10.4 (*p* \> 0.05)   24.1 (*p* \< 0.001)   13.1 (*p* \< 0.05)
  CD45/3 IV UCB                                               1.1                 0.6                  0.1                   0.8
  CD45/3 IV UCB + IM PLX                                      0.4 (*p* \> 0.05)   0.3 (*p* \> 0.05)    0.5 (*p* \> 0.05)     0.8 (*p* \> 0.05)
  CD45/13 IV UCB                                              4.4                 1.8                  1.3                   1.5
  CD45/13 IV UCB + IM PLX                                     6.7 (*p* \> 0.05)   1.2 (*p* \> 0.05)    7.4 (*p* \> 0.05)     3.6 (*p* \> 0.05)
  CD45/14 IV UCB                                              2.2                 1.8                  1.0                   1.0
  CD45/14 IV UCB + IM PLX                                     3.1 (*p* \> 0.05)   0.8 (*p* \> 0.05)    1.4 (*p* \> 0.05)     1.6 (*p* \> 0.05)
  CD45/19 IV UCB                                              1.4                 1                    3.8                   4.1
  CD45/19 IV UCB + IM PLX                                     0.4 (*p* \> 0.05)   1.7 (*p* \> 0.05)    12.6 (*p* \< 0.01)    10.1 (*p* \< 0.01)
  CD41 IV UCB                                                 0.2                 0.4                  0.1                   0
  CD41 IV UCB + IM PLX                                        0.7 (*p* \> 0.05)   0.3 (*p* \> 0.05)    0.7 (*p* \> 0.05)     0.4 (*p* \> 0.05)

*p-Values as compared to the intravenous UCB group*.

![Representative flow cytometry plot of peripheral blood at 8 weeks posttransplant. CD45/CD3 **(A)** CD45/CD13 **(B)**, CD45/CD14 **(C)**, CD45/CD19 **(D)**, and isotype control **(E)**.](fmed-05-00037-g003){#F3}

Posttransplant IM Administration of PLX-R18 Improves Overall Human CD45 Lineage Cell Engraftment in the Bone Marrow {#S3-2}
-------------------------------------------------------------------------------------------------------------------

Within the bone marrow, the IV UCB/IM PLX-R18 cohort demonstrated similar increases in CD45^+^ lineage cells at 8 weeks as compared with the IV hUCB cohort control (28 vs. 40.0%, *p* \< 0.01; Figure [4](#F4){ref-type="fig"}A; Table [2](#T2){ref-type="table"}). In contrast with the peripheral blood, there was no significant difference in B-cells within the bone marrow between cohorts (Figure [4](#F4){ref-type="fig"}E); however, the majority of the CD45^+^ cells were also CD19^+^. The differences between megakaryocytes and platelets were not significance (2.6 vs. 10.2%, *p* \> 0.05; Figure [4](#F4){ref-type="fig"}F; Table [2](#T2){ref-type="table"}), nor were the differences between T-cells, granulocytes, and platelets or megakaryocytes in the bone marrow between either cohorts (Figures [4](#F4){ref-type="fig"}B--D; Table [2](#T2){ref-type="table"}). Representative flow cytometry plots of bone marrow at 8 weeks posttransplant are shown in Figure [5](#F5){ref-type="fig"}. Concurrent histopathologic evaluation demonstrated no difference in overall cellularity, myeloid-to-erythroid ratio, or megakaryocytic percentages between the bone marrow samples of the cohorts at 8 weeks posttransplant (Figure [6](#F6){ref-type="fig"}).

![Posttransplant PLacental eXpanded (PLX)-R18 IM injection improves human leukocyte (CD45) in the bone marrow at 8 weeks. Flow cytometry results of the right tibia bone marrow CD45 **(A)**, CD45/CD3 **(B)**, CD45/CD13**(C)**, CD45/CD14 **(D)**, CD45/19 **(F)**, and CD41 **(E)**. IV UCB, *n* = 10; IV UCB/IM PLX, *n* = 14. IV, intravenous; UCB, umbilical cord blood; IM, intramuscular; \**p* \< 0.05.](fmed-05-00037-g004){#F4}

###### 

Summary of the percent CD45, CD45/3, CD45/13, CD45/14, CD45/19, and CD41 in the bilateral tibial and femoral bone marrow at 8 weeks post umbilical cord blood (UCB) infusion.

                                              CD45 (%)             CD45/3 (%)        CD45/13 (%)         CD45/14 (%)         CD45/19 (%)          CD41 (%)
  ------------------------------------------- -------------------- ----------------- ------------------- ------------------- -------------------- --------------------
  IV UCB                                      28.0                 1.3               3.7                 2.1                 17.4                 2.6
  IV UCB + intramuscular PLacental eXpanded   40.0 (*p* \< 0.05)   0 (*p* \> 0.05)   3.4 (*p* \> 0.05)   1.1 (*p* \> 0.05)   26.2 (*p* \> 0.05)   10.2 (*p* \> 0.05)

*p-Values as compared to the intravenous (IV) umbilical cord blood group*.

![Representative flow cytometry plots of bone marrow at 8 weeks posttransplant. CD45/CD3 **(A)** CD45/CD13 **(B)**, CD45/CD14 **(C)**, CD45/CD19 **(D)**, and isotype control **(E)**.](fmed-05-00037-g005){#F5}

![Histology of the bone marrow from NSG mice treated with intravenous (IV) 5 × 10^5^ umbilical cord blood CD34^+^ cells **(A--C)** and NSG mice treated with IV 5 × 10^5^ UBC CD34^+^ cells and 1 × 10^6^ intramuscular PLacental eXpanded-R18 on D2 and D7 **(D--F)**.](fmed-05-00037-g006){#F6}

Conclusion {#S4}
==========

Our results support the hypothesis that IM injection of PLX-R18 improves the rapidity of human UCB engraftment in NSG mice when given in the posttransplant setting. It is likely that PLX-R18 exert their effect through secretion of pro-differentiation and proliferative cytokines that subsequently exert systemic effects, given that the PLX-R18 cells were injected intramuscularly and not intravenously or intra-osseously ([@B36]). As such, the PLX-R18 cells are unlikely to track into the bone marrow microenvironment. Additional bio-distribution studies of IM PLX-R18 demonstrate that the cells remain local, but few survive beyond 13 weeks past administration (in press).

Consistent with previous experiments by Prather et al., the effect of the PLX-R18 appeared to be transient, as the percentage of CD45^+^ cells declined within the peripheral blood after week 6. This drop off after week 6 likely is the result of exhaustion, death, or clearance of the PLX-R18 cells ([@B34]). Interestingly, though the effect within the peripheral blood appeared transient, the week 8 analysis of the bone marrow did show a significant increase in human engraftment as expressed by CD45^+^ cells, suggesting that marrow engraftment can be enhanced and may be permanent. Cytokine analyses of the serum are ongoing, but *in vivo* experiments demonstrate that PLX-R18 secretes granulocyte-colony stimulating factor, CXCL1, monocyte chemo-attractant protein-1, and interleukin-6; these concentrations peak in the serum at day 9 post-IM injection (in press).

Intravenous instead of IM injection of placental derived MSC combined with hUCB seems to result in similar engraftment outcomes. In an NOD/SCID mouse model of transplant utilizing sub-lethal conditioning, placental derived MSCs grown in a 3D-culture (PLX-I) combined with hUCB resulted in improved engraftment rates in the bone marrow at 6 weeks as measured by CD45^+^ human cells ([@B37]). Experiments involving IV cotransplant of hUCB and MSC has demonstrated improved engraftment rates of CD45^+^ human cells in the peripheral blood and bone marrow of NOD/SCID mice at 6--8 weeks posttransplant ([@B20], [@B38]). Similar to IM PLX-R18 cohort, the majority of the CD45^+^ population of cells in both the bone marrow and the peripheral blood were of the lymphoid lineage when hUCB was co-transplant with MSC. This finding is also consistent with other studies and suggests that PLX-R18 may also improve immune reconstitution following transplant ([@B28], [@B39]).

A detailed histological analysis of the bone marrow did not demonstrate any differences in overall cellularity, megakaryocytic:erythrocytic (M:E) ratio, or the percentages of megakaryocytes among cohorts. In the setting of non-myeloablative radiation, autologous recovery of murine bone marrow cells along with hUCB engraftment would be expected, and PLX-R18 cells may have enhanced the rate of this recovery.

The current therapeutic strategy is intriguing in that it may improve engraftment in patients who have incomplete engraftment after HCT. There is significant evidence in mice that MSC improve hUCB hematopoietic cell engraftment ([@B18], [@B19]). In theory, the observed experimental benefit could be extended to patients whose marrows have experienced delayed or incomplete engraftment. The safety and potential efficacy of IV administration of MSCs has been demonstrated in humans ([@B25], [@B26]). In autologous transplants, autologous MSCs co-infused with HSCs leads to rapid recovery of blood counts ([@B26]). In allogeneic transplantation, Lazarus et al. published a study in which 46 matched related donor transplant patients were infused with matched related culture-expanded MSCs prior to the hematopoietic graft. There were no toxicities associated with infusion of the MSC, and engraftment of neutrophils and platelets occurred at a median time of 14 and 20 days, respectively. In contrast with IV administration of MSC, IM administration of mesenchymal-like PLX cells has been documented to improve hematopoietic recovery in a three-patient cohort study ([@B40]). As such, a translational, a phase I international trial is now underway \[[ClinicalTrials.gov](ClinicalTrials.gov) number NCT03002519\].
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